Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in Type 2 Diabetes and Chronic Kidney Disease
NCT04865770Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2021
- Primary completion
- Nov 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
A Phase 3 trial of semaglutide in chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Apr 2021; status: completed.
02
Drugs
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04865770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04865770.